MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., today announced the launch of an Early Access Program for its cell-free DNA (cfDNA) technology, which enables the detection of neoantigens across an exome (~20,000 genes) from a single blood sample. This is in contrast to other commercial cfDNA approaches focused on tracking fewer than a hundred variants or genes. The technology may enable monitoring of previously detected neoantigens and identification of new ones at multiple time points pre- and post-cancer treatment. The company also stated that the program will be offered exclusively to its immuno-oncology partners.
The Personalis approach for cfDNA analysis is unique in several key areas including:
- Ultra-deep ACE Exome sequencing of cfDNA
- Detection of mutations and putative neoantigens across 20,000 genes
- Focus on late stage tumor characterization, neoantigen detection, and monitoring
Speaking at the Neoantigen Summit in Boston, the company’s Chief Scientific Officer (CSO), Dr. Richard Chen presented data showing the concordance between cfDNA ACE Exome and ACE Exome tumor biopsy results. Dr. Chen said, “One of the challenges facing neoantigen-based vaccine developers today is the inherently heterogeneous and dynamic nature of tumors. We believe that using exome-scale analysis to identify variants in cfDNA, as a complement to our ACE ImmunoID analysis of tissue biopsies, will help identify the optimal neoantigen targets for vaccine development.”
During this Early Access phase, Personalis’ cfDNA ACE Exome sequencing is for Research Use Only.
Personalis’ ACE ImmunoID™ Platform: The platform enables the comprehensive characterization of a tumor’s immuno-genomics including neoantigens, the tumor microenvironment, HLA, immuno-modulators and mechanisms of tumor escape to aid rational vaccine design.
About Personalis, Inc.
Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA certified and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
